Iovance Biotherapeutics, Inc.

Gilead Sciences could learn this week whether the European Medicines Agency will recommend that lenacapavir should be approved for marketing as a twice-yearly preventative option for HIV in the EU as

Gilead Sciences’ Kite division is stepping into cell therapy for solid tumors with encouraging early efficacy data in one of the toughest of all cancers to treat, having presented Phase I results for

With one approved therapy in the US and approximately 75 more in the pipeline, tumor infiltrating lymphocyte (TIL) treatments are a promising new approach to cancer immunotherapy, particularly for sol

The US Food and Drug Administration’s expectations for the timing of accelerated approval confirmatory trials came into clearer focus in 2024 with new policy documents and real-world examples. The age